Agency Information Collection Activities; Proposed Collection; Comment Request; Bar Code Label Requirement for Human Drug and Biological Products, 41817-41818 [E6-11641]
Download as PDF
41817
Federal Register / Vol. 71, No. 141 / Monday, July 24, 2006 / Notices
FDA estimates the burden for this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
No. of
Respondents
21 CFR (Or FDA Form #)
Screening Tool
Annual Frequency
per Response
Total Annual
Responses
Hours per
Response
Total Hours
5,000
5,000
0.05
250
500
1
500
0.25
125
-
Online Survey
1
-
-
Telephone2
Follow-Up
-
Total
375
1There
are no capital costs or operating and maintenance costs associated with this collection of information.
2This was listed in the FEDERAL REGISTER announcement but is no longer required in the survey.
Dated: July 17, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–11640 Filed 7–21–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Bar Code Label
Requirement for Human Drug and
Biological Products
Food and Drug Administration,
HHS.
sroberts on PROD1PC70 with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the bar code label requirements for
human drug and biological products.
DATES: Submit written or electronic
comments on the collection of
information by September 22, 2006.
ADDRESSES: Submit electronic
comments on the collection of
information to: https://www.fda.gov/
dockets/ecomments. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane., rm.
VerDate Aug<31>2005
17:54 Jul 21, 2006
Jkt 208001
Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’ s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
SUPPLEMENTARY INFORMATION:
[Docket No. 2006N–0279]
AGENCY:
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Elizabeth Berbakos, Office of
Management Programs (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
1482.
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Bar Code Label Requirement for
Human Drug and Biological Products
In the Federal Register of February
26, 2004 (69 FR 9120), we issued a new
rule that required human drug product
and biological product labels to have bar
codes. The rule required bar codes on
most human prescription drug products
and on over-the-counter (OTC) drug
products that are dispensed under an
order and commonly used in health care
facilities. The rule also required
machine-readable information on blood
and blood components. For human
prescription drug products and OTC
drug products that are dispensed under
an order and commonly used in health
care facilities, the bar code must contain
the National Drug Code number for the
product. For blood and blood
components, the rule specifies the
minimum contents of the machinereadable information in a format
approved by the Center for Biologics
Evaluation and Research Director as
blood centers have generally agreed
upon the information to be encoded on
the label. The rule is intended to help
reduce the number of medication errors
in hospitals and other health care
settings by allowing health care
professionals to use bar code scanning
equipment to verify that the right drug
(in the right dose and right route of
administration) is being given to the
right patient at the right time.
Most of the information collection
burden resulting from the final rule, as
calculated in table 1 of the final rule (69
FR 9120 at 9149), was a one-time
burden that does not occur after the
rule’s compliance date of April 26,
2006. In addition, some of the
information collection burden estimated
E:\FR\FM\24JYN1.SGM
24JYN1
41818
Federal Register / Vol. 71, No. 141 / Monday, July 24, 2006 / Notices
in the final rule is now covered in other
OMB-approved information collection
packages for FDA. However, parties may
continue to seek an exemption from the
bar code requirement under certain,
limited circumstances. Section
201.25(d) (21 CFR 201.25(d)) requires
submission of a written request for an
exemption and describes the contents of
such requests. Based on the number of
exemption requests submitted during
2004 and 2005, we estimate that
approximately 2 waiver requests may be
submitted annually, and that each
exemption request will require 24 hours
to complete. This would result in an
annual reporting burden of 48 hours.
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
21 CFR Section
No. of Responses Per
Respondent
No. of Respondents
201.25(d)
2
Total Annual
Responses
1
Hours per Response
2
24
Total
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: July 17, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–11641 Filed 7–21–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006N–0277]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Food Labeling;
Notification Procedures for Statements
on Dietary Supplements
AGENCY:
Food and Drug Administration,
HHS.
sroberts on PROD1PC70 with NOTICES
48
48
1There
ACTION:
Total Hours
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the information collection provisions of
the regulation requiring manufacturers,
packers, and distributors of dietary
supplements to notify FDA that they are
marketing a dietary supplement product
that bears on its label or in its labeling
a statement provided for in the Federal
Food, Drug, and Cosmetic Act (the act).
DATES: Submit written or electronic
comments on the collection of
information by September 22, 2006.
ADDRESSES: Submit electronic
comments on the collection of
information to: https://www.fda.gov/
VerDate Aug<31>2005
17:54 Jul 21, 2006
Jkt 208001
dockets/ecomments. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of Management
Programs (HFA–250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–4659.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Food Labeling; Notification Procedures
for Statements on Dietary
Supplements—21 CFR 101.93 (OMB
Control Number 0910–0331)—Extension
Section 403(r)(6) of the act (21 U.S.C
343(r)(6)) requires that the agency be
notified by manufacturers, packers, and
distributors of dietary supplements that
they are marketing a dietary supplement
product that bears on its label or in its
labeling a statement provided for in
section 403(r)(6) of the act. Section
403(r)(6) of the act requires that the
agency be notified, with a submission
about such statements, no later than 30
days after the first marketing of the
dietary supplement. Information that is
required in the submission includes: (1)
The name and address of the
manufacturer, packer, or distributor of
the dietary supplement product; (2) the
text of the statement that is being made;
(3) the name of the dietary ingredient or
supplement that is the subject of the
statement; (4) the name of the dietary
supplement (including the brand name);
and (5) a signature of a responsible
individual who can certify the accuracy
of the information presented, and who
must certify that the information
contained in the notice is complete and
accurate, and that the notifying firm has
substantiation that the statement is
truthful and not misleading.
The agency established § 101.93 (21
CFR 101.93) as the procedural
regulation for this program. Section
101.93 provides details of the
procedures associated with the
submission and identifies the
information that must be included in
order to meet the requirements of
section 403 of the act.
E:\FR\FM\24JYN1.SGM
24JYN1
Agencies
[Federal Register Volume 71, Number 141 (Monday, July 24, 2006)]
[Notices]
[Pages 41817-41818]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-11641]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006N-0279]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Bar Code Label Requirement for Human Drug and
Biological Products
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on the bar code label
requirements for human drug and biological products.
DATES: Submit written or electronic comments on the collection of
information by September 22, 2006.
ADDRESSES: Submit electronic comments on the collection of information
to: https://www.fda.gov/dockets/ecomments. Submit written comments on
the collection of information to the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane., rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Elizabeth Berbakos, Office of
Management Programs (HFA-250), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-827-1482.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA' s estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Bar Code Label Requirement for Human Drug and Biological Products
In the Federal Register of February 26, 2004 (69 FR 9120), we
issued a new rule that required human drug product and biological
product labels to have bar codes. The rule required bar codes on most
human prescription drug products and on over-the-counter (OTC) drug
products that are dispensed under an order and commonly used in health
care facilities. The rule also required machine-readable information on
blood and blood components. For human prescription drug products and
OTC drug products that are dispensed under an order and commonly used
in health care facilities, the bar code must contain the National Drug
Code number for the product. For blood and blood components, the rule
specifies the minimum contents of the machine-readable information in a
format approved by the Center for Biologics Evaluation and Research
Director as blood centers have generally agreed upon the information to
be encoded on the label. The rule is intended to help reduce the number
of medication errors in hospitals and other health care settings by
allowing health care professionals to use bar code scanning equipment
to verify that the right drug (in the right dose and right route of
administration) is being given to the right patient at the right time.
Most of the information collection burden resulting from the final
rule, as calculated in table 1 of the final rule (69 FR 9120 at 9149),
was a one-time burden that does not occur after the rule's compliance
date of April 26, 2006. In addition, some of the information collection
burden estimated
[[Page 41818]]
in the final rule is now covered in other OMB-approved information
collection packages for FDA. However, parties may continue to seek an
exemption from the bar code requirement under certain, limited
circumstances. Section 201.25(d) (21 CFR 201.25(d)) requires submission
of a written request for an exemption and describes the contents of
such requests. Based on the number of exemption requests submitted
during 2004 and 2005, we estimate that approximately 2 waiver requests
may be submitted annually, and that each exemption request will require
24 hours to complete. This would result in an annual reporting burden
of 48 hours.
Table 1.--Estimated Annual Reporting Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
No. of Responses Per Total Annual
21 CFR Section No. of Respondents Respondent Responses Hours per Response Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
201.25(d) 2 1 2 24 48
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total .................... .................... .................... .................... 48
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\There are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: July 17, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6-11641 Filed 7-21-06; 8:45 am]
BILLING CODE 4160-01-S